Oil prices are moving on Strait of Hormuz concerns, and that keeps inflation and interest rate worries on the radar. Many investors are sticking to the sidelines. That creates room for those exploring Financially Fit Penny Stocks, where smaller companies still show healthier balance sheets than many expect at this price level. This article highlights three such penny stocks and explains what makes them stand out on this screener.

These stocks are just a starting sample, with the full Financially Fit Penny Stocks screen surfacing 322 more companies that also pair low share prices with balance sheet strength and cash discipline. If you want to identify higher conviction ideas tailored to your own risk profile, head straight into the Financially Fit Penny Stocks screener.

Enovix (ENVX)

Overview: Enovix is a US based battery company that designs and manufactures lithium ion cells for wearables, smartphones, computing devices, electric vehicles and other original equipment manufacturers. Its technology focuses on higher energy density batteries for uses such as defense applications and smart eyewear.

Operations: Enovix generates about US$34 million in revenue from batteries and battery systems, with most sales tied to South Korea at roughly US$24 million.

Market Cap: US$913 million

Enovix offers exposure to advanced battery technology that targets high value markets such as defense, drones and potential future smartphone and AR/VR devices, while still trading in penny stock territory. The company is moving from proving its technology to scaling production, supported by new manufacturing leadership and a high volume line in Malaysia that is intended to support potential smartphone and smart eyewear launches from 2025. At the same time, Enovix is unprofitable, carries a very high P/S multiple and continues to report sizeable losses, so commercial execution and demand need to catch up. Analysts currently see meaningful upside in their targets, but the key issue is whether Enovix can convert engineering progress into sustainable, higher margin revenue.

Enovix is working to turn high energy density battery technology into real scale, yet the market still treats it as a high risk penny stock story. See how the 1 key reward and 2 important warning signs

Build your own high potential battery and tech shortlist

Enovix and the two other penny stocks in this list all came from one screener, but your best ideas will likely come from filters tuned to your own style. Use our flexible Screener to mix metrics like balance sheet strength, cash flows and risks, or tap into any of our curated Investing Ideas for ready made starting points.

Grab Holdings (GRAB)

Overview: Grab Holdings runs a super app across Southeast Asia that brings together ride hailing, food and grocery delivery, digital payments, banking and lending, insurance, mapping and travel bookings in a single platform used by tens of millions of consumers and merchants.

Market Cap: US$15.3 billion

Grab Holdings gives you exposure to Southeast Asia’s push toward digital transport, food delivery and finance in one ecosystem, backed by a strong cash position, growing adjusted EBITDA over 18 straight quarters and rising net income. The stock trades at a P/E that is well below many peers, despite analysts expecting faster earnings and revenue growth than the broader US market and pointing to a sizable gap to estimated fair value. At the same time, thin GAAP margins, reliance on higher risk funding sources and heavy share issuance keep execution risk high, while ongoing buybacks and insider selling send mixed signals. For investors willing to accept volatility, the mix of scale, fintech upside and recent profitability makes Grab a penny stock worth a closer look.

Grab Holdings now has scale, cash and a P/E that undercuts many peers, yet the market still prices in doubt. See how the 5 key rewards and 1 important major warning sign could reshape that story or expose the one thing investors are missing

Clover Health Investments (CLOV)

Overview: Clover Health Investments provides Medicare Advantage plans in the United States and runs Clover Assistant, a software platform that helps physicians detect and manage chronic diseases for Medicare eligible patients.

Market Cap: US$2.19b

Clover Health Investments is worth a closer look if you want exposure to Medicare Advantage growth tied directly to technology that aims to lower medical costs and improve margins. The company reports fast historical earnings improvement and Q2 2026 results that topped expectations, with raised guidance for revenue, adjusted EBITDA and GAAP net income and a 48% rise in Medicare Advantage membership. At the same time, Clover still reports GAAP losses, faces higher medical and pharmacy costs and operates in a heavily regulated, competitive market. Analysts and the Simply Wall St model see room between current pricing, fair value estimates and future earnings potential, but the real story rests on whether Clover’s tech driven care model can keep medical costs in check as it scales.

Clover Health’s tech driven Medicare story is accelerating; yet the real puzzle is how that model handles rising medical and pharmacy costs at scale. Read the full narrative for Clover Health Investments

Seeking Fresh Alternatives Before They Fly

Markets move fast and fresh opportunities can slip away while you wait. Catch potential breakouts, shifting momentum and under the radar ideas before the crowd, and consider acting promptly.

• Spot companies quietly building strength before momentum headlines catch up by scanning the 19 high quality undiscovered gems while the data still feels under the radar.
• Explore resilient payers that aim to keep income flowing even when prices are dropping by reviewing the curated 8 dividend fortresses for potential high yield candidates.
• Track infrastructure stocks connected to AI driven demand shifts and capital flows by checking the hand picked 55 AI infrastructure stocks while the story is still forming.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.